Monocyte Antigen Carrier Cells for Newly Diagnosed GBM

Summary

The primary purpose of this study is to determine the maximum tolerated dose (MTD) of MT-201-GBM (pp65CMV antigen monocytes) that will be administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O\[6\]-methylguanine-DNA methyltransferase) (MGMT) gene promoter.

Timeline

Start

2023-08

Primary completion

2025-05

Completion

2025-11

Outcome

Outcome not reported

Stopped: “Due to need to proceed with procedural changes with goals of improving the technical and economic feasibility.”

Drugs

Indications